{"id":"NCT00292461","sponsor":"Eisai Inc.","briefTitle":"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures","officialTitle":"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2009-08","completion":"2009-09","firstPosted":"2006-02-16","resultsPosted":"2011-08-15","lastUpdate":"2013-05-20"},"enrollment":64,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Zonisamide","otherNames":[]},{"type":"DRUG","name":"Lamotrigine","otherNames":[]}],"arms":[{"label":"zonisamide","type":"ACTIVE_COMPARATOR"},{"label":"lamotrigine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of zonisamide for anti-epilepsy drugs (AEDs) treated subjects with refractory simple partial, complex partial or partial with secondary generalized seizures.","primaryOutcome":{"measure":"The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline","timeFrame":"Baseline and 16 weeks","effectByArm":[{"arm":"Zonegran","deltaMin":-32.7,"sd":null},{"arm":"Lamotrigine","deltaMin":-35.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.240"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":15},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["dizziness","somnolence","Hepatic enzyme abnormal","rash","diplopia"]}}